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http://www.biomedcentral.com/1746-6148/9/19RESEARCH ARTICLE Open AccessLaboratory capacity for diagnosis of
foot-and-mouth disease in Eastern Africa:
implications for the progressive control pathway
Alice Namatovu1,2, Sabenzia Nabalayo Wekesa3,4, Kirsten Tjørnehøj5, Moses Tefula Dhikusooka1,
Vincent B Muwanika3, Hans Redlef Siegsmund6 and Chrisostom Ayebazibwe1*Abstract
Background: Accurate diagnosis is pertinent to any disease control programme. If Eastern Africa is to work towards
control of foot-and-mouth disease (FMD) using the Progressive Control Pathway for FMD (PCP-FMD) as a tool, then
the capacity of national reference laboratories (NRLs) mandated to diagnose FMD should match this task. This study
assessed the laboratory capacity of 14 NRLs of the Eastern Africa Region Laboratory Network member countries
using a semi-structured questionnaire and retrospective data from the World Reference Laboratory for FMD annual
reports and GenbankW through National Centre for Biotechnology Information for the period 2006–2010.
Results: The questionnaire response rate was 13/14 (93%). Twelve out of the 13 countries/regions had experienced
at least one outbreak in the relevant five year period. Only two countries (Ethiopia and Kenya) had laboratories at
biosecurity level 3 and only three (Ethiopia, Kenya and Sudan) had identified FMD virus serotypes for all reported
outbreaks. Based on their own country/region assessment, 12/13 of these countries /regions were below stage 3 of
the PCP-FMD. Quarantine (77%) and vaccination (54%) were the major FMD control strategies employed. The
majority (12/13) of the NRLs used serological techniques to diagnose FMD, seven used antigen ELISA and three of
these (25%) also used molecular techniques which were the tests most frequently requested from collaborating
laboratories by the majority (69%) of the NRLs. Only 4/13 (31%) participated in proficiency testing for FMD. Four
(31%) laboratories had no quality management systems (QMS) in place and where QMS existed it was still deficient,
thus, none of the laboratories had achieved accreditation for FMD diagnosis.
Conclusions: This study indicates that FMD diagnostic capacity in Eastern Africa is still inadequate and largely
depends on antigen and antibody ELISAs techniques undertaken by the NRLs. Hence, for the region to progress on
the PCP-FMD, there is need to: implement regional control measures, improve the serological diagnostic test
performance and laboratory capacity of the NRLs (including training of personnel as well as upgrading of
equipment and methods, especially strengthening the molecular diagnostic capacity), and to establish a regional
reference laboratory to enforce QMS and characterization of FMD virus containing samples.Background
Foot-and-mouth disease (FMD) is a highly contagious,
acute, vesicular disease of cloven-hoofed domestic and
wild animals [1]. The disease poses significant con-
straints through reduced productivity and limitation of
international trade in live animals and their products
[2,3]. The causal agent, foot-and-mouth disease virus* Correspondence: cayebazibwe@gmail.com
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distribution, and reproduction in any medium(FMDV), belongs to the genus Aphthovirus, in the family
Picornaviridae [4] and exists in seven serotypes; O, A,
C, Asia 1, SAT 1, SAT 2 and SAT 3, with all except Asia
1 having occurred in Africa [5,6]. In Eastern Africa,
serotypes O, A, SAT 1 and SAT 2 are still in circulation
[7-10]. Serotype C was last diagnosed in Kenya in 2004
[11,12] while SAT 3 was last isolated from African buffa-
los (Syncerus caffer) in Uganda in 1997 [13]. However,
the FMD situation is constantly evolving necessitating
regular typing of currently circulating FMDV strains if
effective control measures are to be implemented [14].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Description of the PCP-FMD stages
Stage Description
0 FMD risk is not controlled/there is no reliable information on
FMD
1 Identification of risk and FMD control options
2 Implementation of risk –based control
3 Implementation of control strategy to eliminate circulation
(no endemic FMD)
4 Maintenance of zero circulation and incursion with vaccination
5 Maintenance of zero circulation and incursion without
vaccination
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FMD) tool was developed by FAO/OIE to assist endemic
countries to reduce progressively the impact of FMD
[15], and consists of six stages (0–5) as shown in Table 1
[14]. The main activities of the PCP–FMD tool include:
monitoring circulating serotypes, vaccination and enhan-
cing bio-security. In Eastern Africa, quarantine and vac-
cination are among the existing FMD control strategies
[16,17], however, the effectiveness of quarantine is lim-
ited by inadequate facilities and very weak law enforce-
ment against animal movements [15,17]. Restriction of
animal movements is complicated by social customs
(communal grazing, dowry and pastoralism) [17] and
both legal and illegal cross-border animal movements.
In addition, although, wildlife have been shown to play a
role as a maintenance host for FMDV [7], fences and
vaccination zones around the national parks are absent.
Thus, uncontrolled animal movements are still a major
risk for spreading FMD [18] and transboundary mobility
of FMDV has been proven between East African coun-
tries [9,19]. Hence, there is a need for an integrated re-
gional approach to FMD control [5].
In the absence of the capacity to control FMD through
animal movement restrictions and other biosecurity
measures, vaccination remains the only practical control
strategy [15]. Vaccination was helpful in the control and
eradication of FMD from Europe (up to1991-1992) [20]
and, in combination with livestock movement control,
helped Namibia and Botswana to obtain FMD free zones
without vaccination [5]. However, despite use of vaccin-
ation in Eastern Africa in the past few decades, FMD
outbreaks are still occurring regularly. The majority of
countries in this region use ring vaccination of cattle
after confirming an outbreak (protective vaccination) as
a control strategy, as opposed to the systematic pre-
ventative vaccination schemes recommended for en-
demic countries. Effectiveness of ring vaccination
depends on timely vaccination of all susceptible species
[20] and restriction of animal movements which is diffi-
cult to accomplish. Moreover, the choice of effective vac-
cines should be based on matching field strains withavailable vaccines [21,22], however, due to the lack of
the necessary tests for detection and characterisation of
field strains [23], such vaccine matching is not com-
monly done in the region. Instead vaccination against 2–
4 serotypes is often carried out in an attempt to ensure
protection. In regions where FMD reference laboratories
exist, characterisation of field strains is offered in sup-
port of regional control or eradication programmes
[24,25]. To date, no FMD reference laboratory has been
established in the Eastern Africa region to enable sys-
tematic characterisation of FMD outbreaks. Conse-
quently, samples from outbreaks in these countries can
be submitted to an OIE designated reference laboratory
such as the World Reference Laboratory for FMD
(WRLFMD), Pirbright, UK, for free typing. However, the
extent of regional sample submission and the compe-
tences of the existing Eastern Africa NRLs for diagnosis
of FMD are not well known.
In this study, we attempt to assess the laboratory cap-
acity of the NRLs for FMD in the countries represented in
the Eastern Africa Region Laboratory Network (EARLN)
for FMD with regard to sampling, diagnostic tests used,
quality assurance and management in pursuit of FMD
control.Methods
Study area
The study was carried out among 14 NRLs that handle
diagnosis of FMD in 12 Eastern Africa member countries
of the EARLN, a network which was established in 2010
mainly to develop the available regional laboratory ser-
vices and to inform and guide decision makers on control
of FMD. Each country had one NRL responsible for FMD
diagnosis except for Somalia which encompasses three
regions (Puntland, Somalia and Somaliland) with semi-
autonomous governments and separate NRLs. So the
study endeavoured to cover the 14 NRLs in the region
and Figure 1 shows the 13 NRLs that participated in the
study which are the: Bujumbura National Veterinary La-
boratory (BNVL) in Burundi, National Laboratory of Ani-
mal Disease Diagnostics (NLADD) in Djibouti, National
Animal and Plant Health Laboratory (NAPHL) in Eritrea,
National Animal Health Diagnostic and Investigation
Centre (NAHDIC) in Ethiopia, FMD National Laboratory
(FNL) in Kenya, Galkayo Central Laboratory (GCL) in
Puntland, National Veterinary Laboratory (NVL) in
Rwanda, SOWELPA Central Laboratory (SCL) in Somalia,
Central Veterinary Laboratory (CVL) Hargeisa in Somali-
land, Central Diagnostic Laboratory (CDL) in South
Sudan, National Veterinary Research Institute (VRI) in
Sudan, Central Veterinary Laboratory (CVL) in Tanzania
and National Animal Disease Diagnostic and Epidemi-
ology Centre (NADDEC) in Uganda.
Figure 1 (See legend on next page.)
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Figure 1 Study area. The map shows the location of the 13 participating national reference laboratories (NRL) mandated to diagnose FMD in
the Eastern Africa region (members of the Eastern Africa Regional Laboratory Network (EARLN)). The locations were established using Global
Position system (GPS) coordinates obtained through the questionnaire. The NRLs include: BNVL: Bujumbura National Veterinary Laboratory in
Burundi, NLADD: National Laboratory of Animal Disease Diagnostics, Djibouti, NAPHL: National Animal and Plant Health Laboratory, Eritrea,
NAHDIC: National Animal Health Diagnostic and Investigation Center, Ethiopia, FNL: FMD National Laboratory, Embakasi, Kenya, GCVL: Galkayo
Central Veterinary Laboratory, Puntland, NVL: National Veterinary Laboratory, Rwanda, SCL: SOWELPA Central Laboratory, Somalia, CVL: Central
Veterinary Laboratory, Hargeisa, Somaliland, CDL: Central Diagnostic Laboratory, South Sudan, VRI: Veterinary Research Institute, Sudan, CVL:
Central Veterinary Laboratory, Tanzania and NADDEC: National Animal Disease Diagnostic and Epidemiology Centre, Uganda.
Namatovu et al. BMC Veterinary Research 2013, 9:19 Page 4 of 11
http://www.biomedcentral.com/1746-6148/9/19Study design and data collection
A cross-sectional purposive survey was conducted to as-
sess the laboratory capacity for diagnosis of FMD among
the NRLs in Eastern Africa. Data was collected using a
semi-structured questionnaire (Additional file 1) sent elec-
tronically to one contact person for each of the 14 NRLs
through the coordinator of EARLN. The general introduc-
tion to the questionnaire and any necessary clarifications
were made electronically. The respondents were requested
to give information related to FMD outbreaks and control
strategies in their countries including: occurrence of FMD
outbreaks within the time period (2006–2010), reporting
of FMD outbreaks and means of communication, re-
sponse time for sampling and the personnel involved in
sampling, samples collected, time lag in transportation
and storage of samples, stage of country on PCP-FMD,
FMD control strategies, type and source of vaccines and
policies for FMD control. Further, information on tests
performed, available equipment for FMD diagnosis,
collaborating laboratories and tests requested by NRLs,
average number of samples collected annually, cost of la-
boratory confirmation, biosafety level (BSL), availability of
QMS, accreditation status, participation in FMD profi-
ciency testing and inter-laboratory testing within the
region, servicing and calibration of equipment, monitoring
of sample storage equipment, and staffing and staff devel-
opment strategies was obtained.
The respondents answered by checking boxes with
pre-written options, while additional information
could be given in provided spaces. The filled question-
naires were returned electronically through the Coord-
inator of EARLN and data was entered and analysed
using Microsoft ExcelW. Furthermore, retrospective
data on sample submission and circulating FMDV
serotypes were obtained from publically available an-
nual reports of WRLFMD, Pirbright [26] and from
GenBankW, National Centre for Biotechnology Infor-
mation ( NCBI) [27].
This research is part of a larger on -going strategic pro-
ject ‘Transboundary Animal Diseases in East Africa’. Ethical
approval was granted by the Ministry of Agriculture
Animal Industry and Fisheries (Reference LHE 199/01),
Uganda.Results
The questionnaire response rate was 13 out of the 14
contact persons (93%) of the NRLs responsible for diag-
nosis of FMD in Eastern Africa.
Annual occurrence of FMD in Eastern Africa (2006–2010)
All countries/regions except Djibouti (12/13) had experi-
enced at least one outbreak in the last five years and
seven of these had had outbreaks in each of the 5 years.
FMD outbreaks were exclusively reported by the re-
gional zonal laboratories in Ethiopia and by Veterinary
officers in three countries (Uganda, Sudan and South
Sudan), while for other countries/regions (9/13) both
farmers and Veterinary officers were the sources of
information about FMD outbreaks to the NRLs.
Table 2 summarizes the number of years with FMD out-
breaks, sample submissions to WRLFMD, and the circu-
lating FMDV serotypes in the different countries/regions
during 2006–2010 based on data from WRLFMD annual
reports and NCBI’s GenBankW. Seven out of 12 (58%)
countries/regions that had experienced FMD outbreaks
had inconsistently submitted samples to WRLFMD for
typing, while only three countries (Ethiopia, Kenya and
Sudan) had identified the causal FMDV serotypes for the
all outbreaks identified during these 5 years.
Control of FMD in Eastern Africa
The control strategies for FMD used in these countries/
regions are shown in Table 3. Nine countries/regions
indicated that they were below PCP-FMD stage 3, while
one reported stage 3, two had not yet assessed their
stage and one did not indicate its stage of PCP-FMD.
With the exception of South Sudan which had no FMD
control strategy, two and five countries/regions relied
solely on either vaccination or quarantine, respectively,
while the remaining five used both vaccination and quar-
antine. Of the seven countries/regions that used vaccin-
ation, only Kenya and Tanzania used pre-outbreak
vaccination and post outbreak ring vaccination, while
four countries/regions only used post outbreak ring vac-
cination and one only pre-outbreak vaccination. Only
Kenya and Ethiopia had vaccine production plants and
with exception of Eritrea, which imported vaccines from
Table 2 Occurrence of FMD outbreaks in Eastern Africa (2006–2010)
Country/
Region
Number
of years
with FMD
outbreaks
Sample
submission
to WRL (no.
of years)
FMDV serotypes identified
2006 2007 2008 2009 2010
Burundi 5 0 - - - - -
Djibouti 0 0 - - - - -
Eritrea 5 0 - - - - -
Ethiopia 5 4 Oab Oa, Aa SAT1a, SAT2a Ob, Ab Ob, Ab, SAT2b Ob, SAT2b
Kenya 5 4 Ab, SAT1ab SAT 2a Oa, SAT2a Oab, Ab, SAT 2b Ob, Ab, SAT1b, SAT 2b Ob, Ab SAT1b, SAT 2b
Puntland nr 0 - - - - -
Rwanda 1 1 negb - - - -
Somalia nr 1 - - - negb -
Somaliland nr 0 - - - - -
South Sudan* 5 0 - - - - -
Sudan 3 1 Aa SAT 2ab Oa, SAT 2a - -
Tanzania 5 2 SAT 1b - - - negb
Uganda 5 2 Oa Ob Oa Oa, negb -
nr: NRL did not reply to this question, -: no FMDV serotypes identified in a particular year, neg: negative samples, a: data obtained from NCBI, Gene Bank for
isolates collected during 2006–2010, b: data from annual reports of WRLFMD, Pirbright for 2006–2010. *: the lack of data from South Sudan reflects the very recent
division of Sudan into Sudan and South Sudan in 2011.
Table 3 FMD control strategies in Eastern Africa
Country/
region
Self assessed stage on
PCP-FMD
Existing FMD control
strategies
Burundi 0 quarantine
Djibouti na quarantine
Eritrea 0 vaccinationa
Ethiopia 1 vaccinationb
Kenya 1 quarantine, vaccinationa,b
Puntland 2 quarantine, vaccinationb
Rwanda 3 quarantine, vaccinationb
Somalia 1 quarantine
Somaliland 1 quarantine
South Sudan na none
Sudan 1 quarantine
Tanzania nr quarantine, vaccinationa,b
Uganda 0 quarantine, vaccinationb
na: not assessed, nr: NRL did not reply to this question, a: pre outbreak
(preventive) vaccination, b: post outbreak ring vaccination.
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countries procured non-purified vaccines from Kenya
(data not shown).
FMD sampling in Eastern Africa
Sampling for FMD was done at different times depend-
ing on the purpose. Table 4 summarises sampling in the
different countries/regions following reports of FMD
outbreaks. In 12/13 countries/regions sampling was
done during the acute phase of outbreaks and six and
five of these countries/regions also sampled during the
subacute and chronic phases of outbreaks, respectively,
while the remaining country only sampled during the
subacute phase. However, in some countries sampling
was also done prior to vaccination (2), post vaccination
(1), for research (3) and for surveillance (1). In nine of
the 13 countries/regions, sampling was done within 1–6
days after a report of a new outbreak.
Ethiopia exclusively used technicians for sampling,
while in Djibouti, Puntland, Somalia, Somaliland and
South Sudan field veterinarians participated in the sam-
pling together with the technicians. In other countries
(7), officials from NRLs were involved in sampling, ei-
ther exclusively (Rwanda and Sudan) or together with
various combinations of field veterinarians, technicians,
animal husbandry officers and officers from zonal veter-
inary investigation centres/researchers (Burundi, Eritrea,
Kenya, Tanzania and Uganda). With the exception of
Puntland, all people involved in sampling had been
trained in FMD sampling. Serum was collected in all
countries, either exclusively (3) or in addition to acombination of lesion epithelium/vesicular fluids, oro-
pharyngeal fluids, oral swabs, saliva and whole blood
(10). Of the 12 respondents that answered the question
on the annual number of samples, three, four, one and
four NRLs indicated that <100, 101–500, 501–1000 and
>1000 samples were collected, respectively (Table 4). It
took 1–7 days for samples to get to the NRLs and all the
11 respondents who answered the question on sample
storage during transit, indicated that samples were kept
Table 4 FMD sampling in Eastern Africa
Country/
region
Reporting time for
sampling (days)
When sampling is
done
Samples
collected
Number of samples
Collected annually
Duration of transport of
samples (days)
Burundi 1-6 AC Serum, LEF 101-500 1-2
Djibouti 14 SAC Serum <100 3
Eritrea 21-30 AC, CH Serum, LEF >1000 1-3
Ethiopia 1-6 AC Serum, LEF, OP <100 2-7
Kenya 1-6 AC, post V SAC, CH,
Res, pre V,
Serum, LEF, OP 101-500 1-2
Puntland 1-6 AC Serum, LEF, OS >1000 2-3
Rwanda 1-6 AC Serum 501-1000 1
Somalia 1-6 AC, SAC Serum, LEF >1000 3-4
Somaliland 1-6 AC, SAC Serum, LEF >1000 3-4
South
Sudan
1-6 AC, SAC Serum <100 1-2
Sudan 7 AC, SAC, CH Serum, LEF, OP nr 1-3
Tanzania 2-14 AC, SAC, CH, Res Serum, LEF,OP,
OS, WB
101-500 1-2
Uganda 1-6 AC, CH, pre V Res, Sur Serum, LEF, OP,
OS, SA
101-500 1-2
AC: acute phase of outbreak, SAC: sub acute phase of outbreak, CH: chronic phase of outbreak, pre V: pre - outbreak vaccination, post V: post outbreak
vaccination, Res: research, Sur: surveillance, LEF: lesion epithelium/fluid, OP: oropharyngeal fluids, OS: oral swabs, SA: saliva, WB: whole blood, nr: NRL did not reply
to this question.
Table 5 Reasons for diagnosis of FMD and tests performed at the NRLs and at the collaborating laboratories
Country/
region
Reasons for
diagnosis of
FMD
Tests performed at NRLs Collaborating laboratories Test performed through
Collaboration
Serology FMDV
identification
Serology FMDV identification
Burundi Cob ELISA Ag ELISA nc
Djibouti Sur, Mve NSP - LQCD, Djibouti NSP LPBE PCRa
Eritrea Sur SPCE, LPBE,
NSP
PCRb, VI IAH,Pirbright, UK - Ag ELISA, PCR a, VI,
sequencing
Ethiopia Sur, Vmat, Res LPBE, NSP Ag ELISA, PCRa,b IAH, Pirbright, UK - PCR a,b, VI, Sequencing
Kenya Sur, Vmat, Cob,
Mve, Res
VNT, LPBE,
NSP
Ag ELISA, CFT,
PCRb*, VI
IAH Pirbright, UK - Ag ELISA, PCR a,b,
Sequencing
Puntland Sur, Vmat, VNT Ag ELISA FNL, Kenya VNT -
Rwanda Sur, Vmat, Cob LPBE - OVI, South Africa Pirbright, UK LPBE Ag ELISA, PCR a,b
Somalia Sur, Vmat NSP - FNL, Kenya - Ag ELISA
Somaliland Sur, Vmat NSP - FNL, Kenya - Ag ELISA
South
Sudan
Sur, Vmat, Cob - Ag ELISA FNL, Kenya - PCR a,b** , Sequencing**
Sudan Sur, Vmat, Cob,
Res
VNT, LPBE,
NSP
Ag ELISA, VI IAH, Pirbright, UK VNT, LPBE,
SPCE
Ag ELISA, PCR a,b, VI,
Sequencing
Tanzania Sur,Vmat, Cob, Res SPCE, LPBE,
NSP
Ag ELISA, PCR a,b* BVI, Botswana IAH, Pirbright, UK NSP Ag ELISA, PCR a,b, VI
Sequencing
Uganda Sur, Vmat, Cob,
Res
SPBE, LPBE,
NSP
PCRa,b Lindholm, Denmark IAH, Pirbright, UK
OVI, South Africa
VNT Ag ELISA, sequencing, VI
Cob: confirmation of outbreaks, Sur: surveillance, Mve: monitoring vaccine efficacy, Vmat: vaccine matching, Res: research, PCR: Polymerase Chain Reaction, a: real
time PCR, b: conventional PCR, VI: virus isolation, Ag: antigen, CFT: complement fixation test, LPBE: liquid phase blocking ELISA, NSP: non-structural protein based
antibody ELISA, SPBE: solid phase blocking ELISA, SPCE: solid phase competition ELISA, VNT: virus neutralization test, *:not used for diagnostic but undergoing
validation, -: not done, **:Tests performed by IAH, Pirbright, UK through the collaborating laboratory, nc: no collaboration, LQCD: Lab
quarantin center-Dammerjog.
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nitrogen tanks for storage of virus containing samples.
Diagnosis and confirmation of FMD in the NRLs
All 13 NRLs were able to diagnose FMD but the reasons
for diagnosis of FMD varied: surveillance (12), serotype/
vaccine matching (10), confirmation of outbreaks (7),
monitoring of vaccine efficacy (2) and research (5)
(Table 5). Confirmation of FMD by NRLs was considered
a public good in all countries except Burundi, South
Sudan and Tanzania (data not shown). The estimated cost
for diagnosis of FMD was less than US$50 per sample in
all but Eritrea and Rwanda which estimated the cost at
more than US$100 (data not shown). The cost for FMD
diagnosis was paid by the budgets of NRLs (4), NGO/pro-
jects (3) and the ministry either exclusively (3) or in
combination with NRLs (1) or projects (2), while in the
three countries where FMD diagnosis was not considered
a public good, the cost of the services was charged to the
submitting body (data not shown).
Table 5 summarises the diagnostic tests performed by
the NRLs. All but CDL of South Sudan used serological
diagnostic tests. Only three NRLs (Eritrea, Kenya and
Sudan) used virus isolation, eight used immunological
detection methods including CDL of South Sudan which
exclusively used antigen ELISA and three used nucleic
acid recognition method (PCR). Table 5 also shows the
collaborating laboratories and tests they perform on be-
half of the NRLs. All except BNVL of Burundi had colla-
borations with other laboratories, and the highest levelTable 6 Quality management systems (Biosafety levels and q
among Eastern Africa NRLs
Country/
Region
Bio
safety
Level
(BSL)
Quality assessment Equipment mainten
QMS
Proficiency
testing
Inter
laboratory
testing
Regular
servi-
cing Calibrati
Burundi 1 nr - + - -
Djibouti 2 - - - + +
Eritrea 2 + - - - -
Ethiopia 3 + + - + +
Kenya 3 + + - + -
Puntland good - - + + +
Rwanda 2 - - - - -
Somalia low + - + + +
Somali
land
good + - + + +
South
Sudan
1 - + - + -
Sudan 2 + - - + +
Tanzania 2 + - - - -
Uganda 2 + + - - -
+: yes, -: no, nr: NRL did not reply to this question.of collaboration (58%) was registered with the Institute
for Animal Health (IAH), Pirbright. The tests provided
by the collaborating laboratories were mostly nucleic
acid recognition methods (9), while five, eight and six
NRLs also requested for virus isolation, Antigen ELISA
and serological tests, respectively.
Quality assurance and standardization for FMD in the
NRLs
Quality management systems (QMS), biosafety and
biosecurity in the NRLs
Eight of the 12 NRLs (67%) that responded to the ques-
tion on existence of QMS, indicated they existed, while
four did not have QMS in place (Table 6). None of the
NRLs had been accredited for FMD diagnosis but all ex-
cept BNVL in Burundi had standard operating proce-
dures (SOP) for FMD diagnosis. Only four of 13 NRLs
(31%) participated in annual proficiency tests, while four
other NRLs had participated in inter-laboratory testing
within the region (Table 6). With regard to biosafety
level, most NRLs worked at BSL 1–2, while two (FNL in
Kenya and NAHDIC in Ethiopia) were at BSL 3 (Table 6).
Five of the NRLs (FNL in Kenya, NAHDIC in Ethiopia,
CDL in South Sudan, GCVL in Puntland and NAPHL in
Eritrea) had biosafety /biosecurity manuals in place (data
not shown).
Equipment servicing and maintenance
Five out of the 13 NRLs (38%) did not regularly service
the equipment used in the diagnostic tests for FMDuality assessment, equipment maintenance and staffing)
ance Staff present
on
Monitoring of
sample storage
daily
Veterinarian/
scientific
supervisor
Technical
supervisors
(manager) Technicians
- + - +
- + - +
+ + + +
+ + + +
+ + + +
+ - + -
+ + + +
- - - +
- - - +
+ + + -
- + + +
- + - +
+ + - +
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NRLs and twice a year by one NRL (CDL, South Sudan).
Six NRLs (46%) calibrated their laboratory equipment
yearly and seven monitored their sample storage equip-
ment daily (Table 6).
Staffing and staff development
Apart from FNL in Kenya, all NRLs reported a problem
of understaffing and one (BNVL in Burundi) had no staff
development plans. Ten NRLs had veterinary/scientific
supervisors (Table 6) with qualifications ranging from
bachelor degree to PhD among their available staff, while
three (SOWELPA in Somalia, GCVL in Puntland and
CVL in Hargeisa, Somaliland) did not have any Univer-
sity graduates. Seven NRLs had technical supervisors/la-
boratory managers while six NRLs did not have this
middle management level. In five of the seven NRLs
with technical supervisors (NAPHIL in Eritrea, FNL in
Kenya, GCVL in Puntland, CDL in South Sudan, VRI in
Sudan) some of these had only diplomas and certificate
qualifications. All NRLs, except CDL of South Sudan
and GCVL of Puntland, had technologist/technicians, at
four of these including some with only certificate qualifi-
cation (VRI in Sudan, SOWELPA in Somalia, CVL in
Hargeisa, Somaliland and NLADD in Djibouti). Eight
NRLs had laboratory assistants of certificate qualifica-
tion, and six had administrative assistants/support staff
(data not shown).
Discussion
This study showed that FMD is still endemic in the ma-
jority of the countries/regions in the Eastern Africa re-
gion, and that these countries/regions mainly use
quarantine and post outbreak ring vaccination as FMD
control strategies. Moreover, the majority of the coun-
tries in the region estimated that they were below stage
3 on the PCP-FMD, an important tool for endemic
countries to progressively reduce the presence of FMD
[14,15].
It has previously been established that disease recogni-
tion is essential for any disease control programme [28],
and this is particularly relevant for FMD due to the
seven FMDV serotypes causing clinically indistinguish-
able disease [5] and to FMD being easily confused with
other viral diseases [29,30]. The present study showed
that, in Eastern Africa, the laboratory capacity for FMD,
in terms of tests, equipment and skilled manpower, is
still limited, and thus all reported outbreaks are not
properly serotyped and characterised leading to insuffi-
cient knowledge of the regional FMD status. Other
factors contributing to unclear FMD status include un-
willingness of farmers to pay for diagnosis where it is
not a public good (3), and failure (6) or inconsistency (7)
in submitting samples to WRLFMD, Pirbright, UK, forfree typing, possibly due to logistically complicated and
expensive sample shipment [5]. Moreover, three coun-
tries had received negative results from WRLFMD, prob-
ably due to poor sample quality. Possible reasons for this
could be improper handling during the 1–7 day transit
from the field to the NRLs, which in 10 of the 13 coun-
tries/regions happened in cool boxes with ice packs ra-
ther than in liquid nitrogen, or poor quality sample
storage in the laboratories caused by unreliable power
supplies in most countries/regions. Poor sampling is less
likely, since training in sampling technique had been
provided in 12 countries/regions, including the three re-
ceiving negative results from WRLFMD.
Though three countries in this survey exclusively col-
lected serum during the acute and subacute phases of
outbreaks, the majority of the countries/regions followed
the recommendation of the OIE [22] and collected sam-
ples for demonstration of FMD viral antigen or nucleic
acid during the acute phase of outbreaks; moreover, their
NRLs had either antigen ELISA or PCR set up. However,
success of these tests entirely depends on sample quality
determined by timing and handling of samples [1], and a
number of outbreaks in the region were not serotyped
and/or characterised. All but one of the 13 NRLs relied
on antibody ELISAs, most likely because these tests are
cheap and suitable for working on many samples, re-
quire lower level of biocontainment [22], and neither de-
pend on cell cultures nor on highly sensitive, expensive
and service-requiring PCR-equipment [31].
The most widely used antibody ELISAs were tests for
identification of antibodies against FMDV non structural
proteins (NSP), probably because they are simple and
serotype–independent, and thus good screening tests for
exposure to FMDV antigen [20,32]. These tests can also
differentiate infected from vaccinated animals (DIVA
test) [33], however, in Eastern Africa, interpretation of
NSP-test results is complicated by the frequent use of
non-purified vaccines which elicit antibodies against
NSPs, thereby limiting the DIVA application of these
tests [20,34,35]. Furthermore, antibodies against NSPs
do not appear until day 8–9 after infection [36], thus, to
be useful, these tests should only be used for sera
sampled in the late subacute and chronic phases. More-
over, as demonstrated in both small ruminants [37] and
cattle [33], antibodies against NSPs persist for a long
time, and thus NSP ELISAs do not differentiate well be-
tween present and past infection at individual level.
Eight of the 13 NRLs serotyped antibodies against
FMDV using OIE-recommended tests, i.e. VNT (3),
LPBE (7) and SPCE (1), and one of these also used a
comparable in-house SPBE developed at the National
Veterinary Institute, Lindholm, Denmark [38]. The lim-
ited use of VNT is most likely due to lack of cell culture
facilities, and possibly also to most NRLs working at
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including VNT, show cross reactions [39-41], which have
grave implications for the control of FMD in the Eastern
Africa countries that greatly rely on serology for serotyp-
ing of outbreaks. In endemic situations such cross reac-
tions may be more pronounced due to repeated
vaccination against and/or infection with one or more
FMDV serotypes [42,43]. Moreover, test related cross-
reactivity has been demonstrated for SPBEs in samples
collected 1–3 weeks after experimental infection of naive
calves (unpublished results) and in field sera from unvac-
cinated small ruminants [44], and for LBPE in sera from
bovines [39], hence, there is a need to improve the specifi-
city of the existing serotype-specific antibody ELISAs.
Tests for detection of FMDV can either identify the
serotype directly (antigen ELISA and sequencing) or in
combination with other techniques (VI and PCR). In this
study, nine NRLs had the capacity for the detection of
FMDV while the remaining four NRLs relied on sending
samples abroad for antigen ELISA (3) or to another na-
tional laboratory for PCR (1). The most widespread test
was the antigen ELISA (7), which like the serotype-
specific antibody ELISAs, shows cross reactions between
the FMDV serotypes [45]. The phasing out of the CFT
in the region demonstrates a move towards more mod-
ern methods, which is also evident from the five NRLs
already using or introducing PCR. Only three NRLs used
VI despite this being about as sensitive as PCR [31,46],
most likely for the same reasons as for not using VNT.
Equally few NRLs (3) used real time and/or conventional
RT-PCR in routine diagnosis, which accords with find-
ings in another endemic country, Brazil, where limited
use was attributed to lack of infrastructure, high cost
and anticipated problems of maintaining technically
complicated and service-demanding PCR machines [31].
The majority of the NRLs (12) collaborated with for-
eign laboratories, including WRLFMD in UK, OVI in
South Africa and FNL in Kenya, to complement their
own diagnostic services. However, Rweyemamu et al.
[15] maintained that relying on foreign technical assist-
ance to manage disease control programs may not be
sustainable in developing countries, and experience from
the region confirms this as the number of samples ana-
lysed is insufficient to get adequately detailed knowledge
of the circulating FMDV strains to implement suffi-
ciently efficient control measures to reduce FMD in the
region. Moreover, recent evidence of the transboundary
nature of FMD in Eastern Africa [9] points to a need for
assuming a regional approach to achieve more efficient
control of FMD and progress on the PCP-FMD.
Eight NRLs had a quality management system (QMS)
in place and had participated in laboratory comparisons,
either inter-laboratory tests or proficiency tests. In
Europe, QMSs are considered essential for diagnosis ofFMD [47,48] including focus on competent, motivated
staff, organisational management, functional equipment,
process control and biosafety/biosecurity [49]. In the
Eastern Africa region, although only one of the 13 NRLs
entirely lacked SOPs, all had deficient QMS as equip-
ment was not regularly serviced in five and not cali-
brated in six NRLs, and six did not monitor sample
storage equipment daily. This can lead to unreliable
equipment and inconsistent quality of samples, which
may affect the results of the performed tests [48]. More-
over, none of the NRLs had been accredited for FMD
diagnosis, including those in countries with vaccine
production plants, and most laboratory comparisons
were arranged by laboratories outside the region with a
more worldwide focus. Thus, QMS efforts could be
strengthened substantially by setting up a regional refer-
ence laboratory for FMD, which would arrange local
comparative inter-laboratory tests with relevance for the
region, encourage QMS and promote virus characterisa-
tion among the NRLs [25].
Many diagnostic laboratories also have consultative/
advisory and disease surveillance roles [28], and its
recommended to build a team of national experts for
these tasks [15]. However, in this study, 12 NRLs were
understaffed, disclosing a clear regional need to address
capacity building in terms of laboratory space, equip-
ment and training of professional and technical staff, as
is currently being carried out by collaborative projects in
Uganda and Kenya (TADEA, DANIDA-funded) and in
Tanzania (SADC TADs, Wellcome Trust- funded), and
as has been initiated for the entire region by FAO organ-
izing the NRLs into a network (EARLN).
OIE recommends that FMD diagnosis is carried out in
OIE class 4 facilities [25,50] and this is generally adhered
to in the FMD-free countries. However, most Eastern
African NRLs were working below BSL 3 including
seven NRLs undertaking virological tests to diagnose
FMD. Moreover, the recommendations for developing
biosafety manuals and adopting biosafety policies [51],
were only implemented at five NRLs. The low level of
biosafety and biosecurity measures could result in escape
of FMDV as happened in the 2007 UK FMD outbreak
[52], and it may be speculated that a (presumably small)
proportion of the outbreaks in Eastern Africa may be
due to poor laboratory biocontainment.
Conclusions
The overall status of FMD in the region remains obscure
due to insufficient diagnostic capacity, leading to lack of
regular typing of outbreak strains. The NRLs largely de-
pend on antigen and antibody ELISAs, supplemented by
varying levels of virus identification and characterisation
performed by international laboratories; moreover, they
do not prioritize QMSs and none of them are accredited
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NRLs, including training of personnel and upgrading
equipment and diagnostic methods, to ensure accurate,
reliable and correctly interpreted results. More reliable
results would also provide an enhanced background for
more narrow selection of vaccine strains/serotypes,
which would reduce costs of FMD vaccination cam-
paigns and could lead to increased numbers of vacci-
nated animals.
Moreover, a regionally coordinated FMD control strat-
egy should be implemented to ascertain sustainable im-
pact of national efforts to improve according to the
PCP-FMD, including the establishment of a regional
reference laboratory to oversee QMS and promote the
characterization of FMDV.Additional file
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